2024-09-18 - Analysis Report
##  MRK Stock Analysis

**Company Overview:** MRK is **Merck & Co., Inc.**, a global pharmaceutical company known for developing and manufacturing prescription drugs, vaccines, and animal health products.

**Performance Analysis:**

**1. Performance Comparison with S&P 500 (VOO):**

* MRK's cumulative return is **52.1%**, while VOO's is **88.56%**.
* MRK has underperformed VOO by **-36.46%**. 
* This places MRK at the **38.61%** percentile of its historical performance against VOO.

**2. Recent Price Action:**

* **Closing price:** 118.03
* **5-day moving average:** 116.36
* **20-day moving average:** 116.59
* **60-day moving average:** 120.26

**3. Technical Indicators:**

* **RSI:** 55.23, suggesting a neutral market momentum.
* **PPO:** 0.28, indicating potential upside momentum.
* **Delta_Previous_Relative_Divergence:** 4.66, signaling a recent short-term upward trend.
* **Expected Return:** 11.82%, representing the potential 5-year expected return on investment. 

**4. Recent Earnings and Outlook:**

| Date       | EPS   | Revenue        |
|------------|-------|-----------------|
| 2024-08-05 | 2.15  | 16.11 B$       |
| 2024-05-03 | 1.88  | 15.78 B$       |
| 2023-11-03 | 1.87  | 15.96 B$       |
| 2023-08-07 | -2.35 | 15.04 B$       |
| 2024-08-05 | -2.35 | 15.04 B$       |

* **Most recent earnings:**  EPS of 2.15 surpassed analyst estimates of 1.95, indicating strong performance.

**Overall Analysis:**

MRK's recent performance has been relatively weak compared to the broader market, as indicated by its underperformance against VOO. However, recent positive earnings results suggest potential for improved performance moving forward. Technical indicators suggest a neutral to slightly bullish outlook with short-term upward momentum. The expected return of 11.82% over five years is encouraging for long-term investors. Further analysis of MRK's specific products and market dynamics is needed for a more comprehensive understanding. 
